Valneva (NASDAQ:VALN) Downgraded by Bryan, Garnier & Co

Valneva (NASDAQ:VALN) was downgraded by equities researchers at Bryan, Garnier & Co from a “buy” rating to a “neutral” rating in a report issued on Monday, The Fly reports.

A number of other brokerages have also weighed in on VALN. Guggenheim began coverage on Valneva in a research report on Monday, May 31st. They issued a “buy” rating and a $35.00 target price for the company. Kepler Capital Markets reissued a “buy” rating on shares of Valneva in a research report on Wednesday, June 30th. Zacks Investment Research lowered Valneva from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 14th. The Goldman Sachs Group began coverage on Valneva in a research report on Tuesday, June 1st. They issued a “buy” rating and a $34.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of Valneva in a research report on Tuesday, June 1st. They set a “buy” rating and a $36.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.00.

Shares of Valneva stock opened at $29.00 on Monday. The stock has a 50-day moving average price of $32.79. Valneva has a 1 year low of $24.16 and a 1 year high of $59.15. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.62.

Valneva (NASDAQ:VALN) last issued its earnings results on Tuesday, August 10th. The company reported ($1.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($1.16). The business had revenue of $29.26 million during the quarter, compared to analyst estimates of $20.98 million. As a group, analysts expect that Valneva will post 2.23 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in shares of Valneva during the 2nd quarter valued at about $259,000. Citadel Advisors LLC bought a new position in shares of Valneva during the 2nd quarter valued at approximately $5,138,000. Tudor Investment Corp Et Al bought a new position in shares of Valneva during the 2nd quarter valued at approximately $203,000. Laurion Capital Management LP bought a new position in shares of Valneva during the 2nd quarter valued at approximately $659,000. Finally, CVI Holdings LLC bought a new position in shares of Valneva during the 2nd quarter valued at approximately $1,486,000. 1.60% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium.

Further Reading: What is the price-sales ratio?

The Fly logo

Analyst Recommendations for Valneva (NASDAQ:VALN)

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.